Our results suggest that PARP inhibition by olaparib and its combination with cisplatin has profound anticancer effect and anti-metastatic effect and may be used as therapeutic strategy in treatment of advanced cervical carcinoma. The gene discussed is PARP1; the disease is cervical carcinoma.